By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment bank Oppenheimer has initiated coverage of Genomic Health, Thermo Fisher Scientific, and Fluidigm.

In a research note issued after the close of the market on Tuesday, analyst David Ferreiro placed a Perform rating on Genomic Health and a 12- to 18-month price target on its stock of $20. He estimated the firm's 2011 EPS at $.11 on revenues of $204.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.